% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{HernndezSnchez:291455,
      author       = {A. Hernández-Sánchez and T. González and M. Sobas and E.
                      Sträng and G. Castellani and M. Abáigar and P. J. M. Valk
                      and Á. Villaverde Ramiro and A. Benner$^*$ and K. H.
                      Metzeler and R. Azibeiro and J. M. Tettero and J.
                      Martínez-López and M. Pratcorona and J. Martínez Elicegui
                      and K. I. Mills and C. Thiede and G. Sanz and K. Döhner and
                      M. Heuser and T. Haferlach and A. T. Turki and D. Reinhardt
                      and R. Schulze-Rath and M. Barbus and J. M. Hernández-Rivas
                      and B. Huntly and G. Ossenkoppele and H. Döhner and L.
                      Bullinger},
      title        = {{R}earrangements involving 11q23.3/{KMT}2{A} in adult
                      {AML}: mutational landscape and prognostic implications - a
                      {HARMONY} study.},
      journal      = {Leukemia},
      volume       = {38},
      number       = {9},
      issn         = {0887-6924},
      address      = {London},
      publisher    = {Springer Nature},
      reportid     = {DKFZ-2024-01418},
      pages        = {1929-1937},
      year         = {2024},
      note         = {2024 Sep;38(9):1929-1937},
      abstract     = {Balanced rearrangements involving the KMT2A gene (KMT2Ar)
                      are recurrent genetic abnormalities in acute myeloid
                      leukemia (AML), but there is lack of consensus regarding the
                      prognostic impact of different fusion partners. Moreover,
                      prognostic implications of gene mutations co-occurring with
                      KMT2Ar are not established. From the HARMONY AML database
                      205 KMT2Ar adult patients were selected, 185 of whom had
                      mutational information by a panel-based next-generation
                      sequencing analysis. Overall survival (OS) was similar
                      across the different translocations, including
                      t(9;11)(p21.3;q23.3)/KMT2A::MLLT3 (p = 0.756). However,
                      independent prognostic factors for OS in intensively treated
                      patients were age >60 years (HR 2.1, p = 0.001), secondary
                      AML (HR 2.2, p = 0.043), DNMT3A-mut (HR 2.1, p = 0.047) and
                      KRAS-mut (HR 2.0, p = 0.005). In the subset of patients with
                      de novo AML < 60 years, KRAS and TP53 were the
                      prognostically most relevant mutated genes, as patients with
                      a mutation of any of those two genes had a lower complete
                      remission rate $(50\%$ vs $86\%,$ p < 0.001) and inferior OS
                      (median 7 vs 30 months, p < 0.001). Allogeneic hematopoietic
                      stem cell transplantation in first complete remission was
                      able to improve OS (p = 0.003). Our study highlights the
                      importance of the mutational patterns in adult KMT2Ar AML
                      and provides new insights into more accurate prognostic
                      stratification of these patients.},
      cin          = {C060},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:38965370},
      doi          = {10.1038/s41375-024-02333-4},
      url          = {https://inrepo02.dkfz.de/record/291455},
}